AYTU BioPharma
AYTU
42 hedge funds and large institutions have $25.7M invested in AYTU BioPharma in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 1 reducing their positions, and 26 closing their positions.
1,800% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 1
84% more capital invested
Capital invested by funds: $14M → $25.7M (+$11.8M)
1.2% more ownership
Funds ownership: 0.05% → 1.25% (+1.2%)
26% less funds holding
Funds holding: 57 → 42 (-15)
54% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$12.7M |
| 2 |
AC
Armistice Capital
New York
|
+$12.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.08M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$752K |
| 5 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
+$452K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$118K |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$109K |
| 3 |
Jane Street
New York
|
-$68K |
| 4 |
VCA
Verdence Capital Advisors
Hunt Valley,
Maryland
|
-$67K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$40K |
AYTU Hedge Fund Activity: Q4 2020 in Review
42 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q4 2020, worth a combined $25.7M — up 84% from $14M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of AYTU and 12 opened new positions — a net loss of 14 holders — while 1 trimmed existing stakes and 19 added.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $12.7M. The largest seller was Nuveen, exiting entirely with an estimated $118K sold.
- 42 institutional investors held AYTU BioPharma (AYTU) as of Q4 2020, down from 57 in Q3 2020.
- Funds reported $25.7M of AYTU BioPharma stock for Q4 2020, up 84% quarter-over-quarter.
- 12 funds opened new AYTU BioPharma positions in Q4 2020 and 26 closed out, a net change of -14 holders.
- The largest AYTU BioPharma buyer in Q4 2020 was Stonepine Capital Management, an estimated $12.7M added.
- The largest AYTU BioPharma seller in Q4 2020 was Nuveen, an estimated $118K sold.
Based on aggregated 13F filings for Q4 2020.